Читать книгу The Peripheral T-Cell Lymphomas - Группа авторов - Страница 3

1 Chapter 2Table 2.1 Main nodal and extranodal mature T‐cell neoplasms with summary of t...

2 Chapter 3Table 3.1 Classes of histone deacetylase inhibitor (HDACi).Table 3.2 Single agents targeting the T‐cell lymphoma epigenome.Table 3.3 Combination agents targeting the T‐cell lymphoma epigenome.

3 Chapter 4Table 4.1 Mouse models of peripheral T‐cell lymphomas (PTCL)

4 Chapter 5Table 5.1 Major lymphoma subtypes by geographic region

5 Chapter 8Table 8.1 Peripheral T‐cell lymphoma not otherwise specified molecular subgroup...

6 Chapter 9Table 9.1 Characteristic of patients with angioimmunoblastic T‐cell lymphoma ...Table 9.2 Frequency of mutations of genes implicated in DNA methylation in an...

7 Chapter 10Table 10.1 Clinical features of anaplastic large‐cell lymphomas.Table 10.2 Pathological and molecular features of anaplastic large‐cell lymph...Table 10.3 Current treatment of anaplastic large‐cell lymphoma.Table 10.4 Future directions for treatment of anaplastic large‐cell lymphoma.

8 Chapter 11Table 11.1 Prospective clinical trials for aggressive adult T‐cell leukemia/l...Table 11.2 Meta‐analysis of interferon alpha plus zidovudine for adult T‐cell...

9 Chapter 12Table 12.1 Chemoradiotherapy regimens for stage IE/IIE nasal extranodal natur...

10 Chapter 13Table 13.1 Outcomes of stem‐cell transplants in published patient series.

11 Chapter 14Table 14.1 Current treatments in large granular lymphocyte leukemia [1, 3].Table 14.2 The future of treatment in large granular lymphocyte leukemia.

12 Chapter 17Table 17.1 Association of hepatosplenic T‐cell lymphoma and immunosuppression...Table 17.2 Summary of outcomes in case series of hepatosplenic T‐cell lymphom...

13 Chapter 19Table 19.1 Classification of Epstein–Barr virus‐positive T‐cell and NK‐cell p...

14 Chapter 20Table 20.1 Risk factors and prognostic models for peripheral T‐cell lymphomas...

15 Chapter 21Table 21.1 Clinical activity of US Federal Drug Administration‐approved singl...Table 21.2 Clinical activity of US Federal Drug Administration‐approved singl...Table 21.3 Clinical activity of US Federal Drug Administration‐approved singl...

16 Chapter 22Table 22.1 Risk of bias summary: review authors’ judgments of each risk of bi...Table 22.2 Clinical studies on the use of autologous stem‐cell transplant for...

17 Chapter 23Table 23.1 Results of allogeneic stem‐cell transplantation in patients with r...Table 23.2 Results of allogeneic stem‐cell transplantation in patients affect...

18 Chapter 24Table 24.1 Selected immunotherapy agents in relapsed peripheral T‐cell lympho...

19 Chapter 25Table 25.1 Experiences with new agents in peripheral T‐cell lymphoma.

20 Chapter 26Table 26.1 T cell lymphoma at diagnosis.Table 26.2 Frequency of lymphoma subtypes according to different data sources...Table 26.3 Overall and progression free survival rates for different T‐cell l...Table 26.4 Survival rates and prognostic factors by different subtypes report...Table 26.5 Available data sources.Table 26.6 Frequency of different lymphoma subtypes and outcomes reported in ...

21 Chapter 27Table 27.1 Activity of the new drug combinations in mature T‐cell lymphoma.Table 27.2 Clinical trials presently exploring novel agents in relapsed/refra...